Skip to main content

Advertisement

Table 2 Laboratory analyses according to paraoxonase genotype subgroups

From: Effects of paraoxonase activity and gene polymorphism on coronary vasomotion

Variable (n= 18) Group 1a
(n= 7)
Group 2b
(n= 5)
Group 3c
(n= 6)
p value*
LDL-cholesterol (mmol/L) 2.3 ± 0.9 2.5 ± 0.6 2.1 ± 0.3 0.71
HDL-cholesterol (mmol/L) 1.1 ± 0.3 1.0 ± 0.1 1.3 ± 0.3 0.16
Triglyceride levels (mmol/L) 2.1 ± 0.7 1.7 ± 0.8 2.1 ± 2.5 0.90
Fastening insulin (μU/mL) 26.2 ± 15.0 23.2 ± 17.9 40.3 ± 55.0 0.67
Fastening glucose (mmol/L) 8.3 ± 3.7 8.7 ± 2.5 7.7 ± 2.9 0.86
HOMA-IR (1) 11.0 ± 10.9 8.8 ± 6.8 18.6 ± 32.8 0.70
hsCRP (mg/L, normal < 5 mg/L) 5.6 ± 7.1 5.6 ± 5.7 1.6 ± 1.9 0.36
PON1 activity (U/L) 51.1 ± 35.3 11.9 ± 6.7 168 ± 27 <0.0001
Arylesterase (U/L) 46.5 ± 14.0 36.2 ± 8.9 45.9 ± 5.5 0.22
Ratio hsCRP/PON1 × 1,000 (mg/U) 365 ± 774 401 ± 254 10.0 ± 12.5 0.37
  1. *p Values were calculated using one-way analysis of variance. aGroup1 = wild type + LM/QR heterozygotes; bgroup 2 = MM homozygotes; cgroup 3 = RR homozygotes; PON1, paraoxonase 1; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment- insulin resistance; hsCRP, high sensitivity C-reactive protein; MM, methionine-methionine; RR, arginine-arginine.